Quinoxaline-1,4-dioxide derivatives inhibitory action in melanoma and brain tumor cells

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Pereira JA, Pessoa AM, Cordeiro MNDS et al. Quinoxaline, its derivatives and applications: a state of the art review. Eur. J. Med. Chem. 97, 664–672 (2015). • Review on the biological effects and pharmacological applications of quinoxalines.
  Medline CASGoogle Scholar
• 2 Cheng G, Sa W, Cao C et al. Quinoxaline 1,4-di-N-oxides: biological activities and mechanisms of actions. Front. Pharmacol. 7(MAR), 64 (2016).
  MedlineGoogle Scholar
• 3 Vicente E, Villar R, Pérez-Silanes S, Aldana I, Goldman RC, Mong A. Quinoxaline 1,4-di-N-oxide and the potential for treating tuberculosis. Infect. Disord. Drug Targets 11(2), 196–204 (2011).
  Medline CASGoogle Scholar
• 4 Huang XJ, Zhang HH, Wang X et al. ROS mediated cytotoxicity of porcine adrenocortical cells induced by QdNOs derivatives in vitro. Chem. Biol. Interact. 185(3), 227–234 (2010).
  Medline CASGoogle Scholar
• 5 Vieira M, Pinheiro C, Fernandes R, Noronha JP, Prudêncio C. Antimicrobial activity of quinoxaline 1,4-dioxide with 2- and 3-substituted derivatives. Microbiol. Res. 169(4), 287–293 (2014). •• Describes the antimicrobial activity of the quinoxaline-1,4-dioxide derivatives used in this study.
  Medline CASGoogle Scholar
• 6 Santivañez-Veliz M, Pérez-Silanes S, Torres E, Moreno-Viguri E. Design and synthesis of novel quinoxaline derivatives as potential candidates for treatment of multidrug-resistant and latent tuberculosis. Bioorg. Med. Chem. Lett. 26(9), 2188–2193 (2016).
  Medline CASGoogle Scholar
• 7 Al-Marhabi A, Abbas H-A, Ammar Y. Synthesis, characterization and biological evaluation of some quinoxaline derivatives: a promising and potent new class of antitumor and antimicrobial agents. Molecules 20(11), 19805–19822 (2015).
  Medline CASGoogle Scholar
• 8 Gu W, Wang S, Jin X et al. Synthesis and evaluation of new quinoxaline derivatives of dehydroabietic acid as potential antitumor agents. Molecules 22(7), 1154 (2017). •• Reviews/reports on the anticancer activity of quinoxaline derivatives.
  Google Scholar
• 9 Patel NB, Patel JN, Purohit AC et al. In vitro and in vivo assessment of newer quinoxaline–oxadiazole hybrids as antimicrobial and antiprotozoal agents. Int. J. Antimicrob. Agents 50(3), 413–418 (2017).
  Medline CASGoogle Scholar
• 10 Miller E, Xia Q, Cella M et al. Voltammetric study of some 3-aryl-quinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives with anti-tumor activities. Molecules 22(9), 1442 (2017).
  Google Scholar
• 11 Tariq S, Alam O, Amir M. Synthesis, anti-inflammatory, p38α MAP kinase inhibitory activities and molecular docking studies of quinoxaline derivatives containing triazole moiety. Bioorg. Chem. 76, 343–358 (2018).
  Medline CASGoogle Scholar
• 12 Marzano C, Pellei M, Tisato F, Santini C. Anti-cancer agents in medicinal chemistry. Anticancer Agents Med. Chem. 9(2), 185–211 (2009). •• Reviews/reports on the anticancer activity of quinoxaline derivatives.
  Medline CASGoogle Scholar
• 13 Liu Z-Y, Sun Z-L. The metabolism of carbadox, olaquindox, mequindox, quinocetone and cyadox: an overview. Med. Chem. 9(8), 1017–1027 (2013). •• Reviews/reports on the anticancer activity of quinoxaline derivatives.
  MedlineGoogle Scholar
• 14 El Aissi R, Liu J, Besse S et al. Synthesis and biological evaluation of new quinoxaline derivatives of ICF01012 as melanoma-targeting probes. ACS Med. Chem. Lett. 5(5), 468–473 (2014).
  Medline CASGoogle Scholar
• 15 Mielcke TR, Mascarello A, Filippi-Chiela E et al. Activity of novel quinoxaline-derived chalcones on in vitro glioma cell proliferation. Eur. J. Med. Chem. 48, 255–264 (2012).
  Medline CASGoogle Scholar
• 16 Abbas H-AS, Al-Marhabi AR, Eissa SI, Ammar YA. Molecular modeling studies and synthesis of novel quinoxaline derivatives with potential anticancer activity as inhibitors of c-Met kinase. Bioorg. Med. Chem. 23(20), 6560–6572 (2015).
  Medline CASGoogle Scholar
• 17 Gao H, Wang D, Zhang S et al. Roles of ROS mediated oxidative stress and DNA damage in 3-methyl-2-quinoxalin benzenevinylketo-1, 4-dioxide-induced immunotoxicity of Sprague–Dawley rats. Regul. Toxicol. Pharmacol. 73(2), 587–594 (2014).
  Google Scholar
• 18 Ahmed HEA, Ihmaid SK, Omar AM et al. Design, synthesis, molecular docking of new lipophilic acetamide derivatives affording potential anticancer and antimicrobial agents. Bioorg. Chem. 76, 332–342 (2018).
  Medline CASGoogle Scholar
• 19 Guo W, Hao H, Dai M et al. Development of quinoxaline 1, 4-dioxides resistance in escherichia coli and molecular change under resistance selection. PLoS ONE 7(8), e43322 (2012).
  Medline CASGoogle Scholar
• 20 Pettersen EO, Ebbesen P, Gieling RG et al. Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: The METOXIA Consortium. J. Enzyme Inhib. Med. Chem. 30(5), 689–721 (2015).
  Medline CASGoogle Scholar
• 21 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646–74 (2011).
  Medline CASGoogle Scholar
• 22 Xu XD, Shao SX, Jiang HP et al. Warburg effect or reverse warburg effect? A review of cancer metabolism. Oncol. Res. Treat. 38(3), 117–122 (2015).
  Medline CASGoogle Scholar
• 23 Mantovani A. Cancer: inflaming metastasis. Nature 457(7225), 36–37 (2009).
  Medline CASGoogle Scholar
• 24 Ramli Y, Moussaif A, Karrouchi K, Essassi EM. Pharmacological profile of quinoxalinone. J. Chem. 2014(563406), 1–21 (2014).
  Google Scholar
• 25 Husain A, Madhesia D. Recent advances in pharmacological activities of quinoxaline derivatives. J. Pharm. Res. 4(3), 924–929 (2011).
  CASGoogle Scholar
• 26 Zhang M, Dai ZC, Qian SS et al. Design, synthesis, antifungal, and antioxidant activities of (E)-6-((2-phenylhydrazono)methyl)quinoxaline derivatives. J. Agric. Food Chem. 62(40), 9637–9643 (2014).
  Medline CASGoogle Scholar
• 27 Moarbess G, Deleuze-Masquefa C, Bonnard V et al. In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives. Bioorganic Med. Chem. 16(13), 6601–6610 (2008).
  Medline CASGoogle Scholar
• 28 Tseng C-H, Chen Y-R, Tzeng C-C et al. Discovery of indeno[1,2- b ]quinoxaline derivatives as potential anticancer agents. Eur. J. Med. Chem. 108, 258–273 (2016).
  Medline CASGoogle Scholar
• 29 Deleuze-Masquefa C, Moarbess G, Khier S et al. New imidazo[1,2-a]quinoxaline derivatives: synthesis and in vitro activity against human melanoma. Eur. J. Med. Chem. 44(9), 3406–3411 (2009).
  Medline CASGoogle Scholar
• 30 Khier S, Deleuze-Masquéfa C, Moarbess G et al. Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma. Eur. J. Pharm. Sci. 39(1–3), 23–29 (2010).
  Medline CASGoogle Scholar
• 31 Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl.) 3, 83–92 (2015).
  MedlineGoogle Scholar
• 32 Junnotula V, Sarkar U, Sinha S, Gates KS. Initiation of DNA strand cleavage by 1,2,4-benzotriazine 1,4-dioxide antitumor agents: mechanistic insight from studies of 3-methyl-1,2,4-benzotriazine 1,4-dioxide. J. Am. Chem. Soc. 131(3), 1015–1024 (2009).
  Medline CASGoogle Scholar
• 33 Garbe C, Peris K, Hauschild A et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – update 2016. Eur. J. Cancer 63(2), 201–217 (2016).
  MedlineGoogle Scholar
• 34 Vartanian A, Baryshnikova M, Burova O et al. Inhibitor of vasculogenic mimicry restores sensitivity of resistant melanoma cells to DNA-damaging agents. Melanoma Res. 27(1), 8–16 (2017).
  Medline CASGoogle Scholar
• 35 Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin. Cancer Res. 15(2), 425–430 (2009).
  Medline CASGoogle Scholar
• 36 Hugo W, Zaretsky JM, Sun L et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165(1), 35–44 (2016).
  Medline CASGoogle Scholar
• 37 Urosevic-Maiwald M, Barysch MJ, Cheng PF et al. In vivo profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma. Oncoimmunology 4(2), e988458 (2015).
  MedlineGoogle Scholar